TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first Company sponsored Phase I study of its novel, orally available and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for EnrollmentNovember 13, 2018 7:30 AM TG Therapeutics (TGTX) Reports Q3 Loss of $0.43November 9, 2018 7:35 AM